SIC
RCKT icon

SJS Investment Consulting’s Rocket Pharmaceuticals RCKT Stock Holding History

SJS Investment Consulting’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63K Buy
477
+282
+145% +$938 ﹤0.01% 1854
2026
Q1 		$699 Buy
+195
New +$775 ﹤0.01% 1606

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SJS Investment Consulting's RCKT Position: Q2 2026 in Review

SJS Investment Consulting increased its Rocket Pharmaceuticals (RCKT) stake by 145% in Q2 2026, buying an estimated $938 and bringing the position to 477 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1854.

SJS Investment Consulting first reported a position in RCKT in Q1 2026 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • SJS Investment Consulting held 477 shares of Rocket Pharmaceuticals worth $1.63K as of Q2 2026.
  • SJS Investment Consulting bought 282 Rocket Pharmaceuticals shares in Q2 2026, an estimated $938.
  • Rocket Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1854 holding.
  • SJS Investment Consulting first reported a position in Rocket Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.